Prescription Drug Review - Brainstem Stroke, 67M

Drug Identification (What Each Drug Is)

ISSUE 1 - DRUG DUPLICATION (CRITICAL)

A. Thiamine Duplication - HIGH PRIORITY

Action: Discontinue the standalone Thiamine injection if Optineuron is continued, OR replace Optineuron with standalone B12/B6 if high-dose thiamine is specifically required (e.g., for suspected Wernicke's encephalopathy, where 100-500mg TID is needed - in that case Optineuron's dose would be inadequate anyway).

B. Dual Insulin Prescription - POTENTIAL DUPLICATION / ERROR

• Risk of dose confusion and double administration
• Concentration mismatch: Actrapid is 40 IU/ml, NovoRapid is 100 IU/ml - using the wrong syringe with the wrong concentration will result in a 2.5x dosing error

Action: Clarify intent - is only one meant to be used? If a sliding scale is needed, specify ONE insulin product, the concentration, and the sliding scale range. The 40 IU/ml vs 100 IU/ml difference is a well-known source of fatal insulin errors.

ISSUE 2 - DRUG-DRUG INTERACTIONS (DDI)

A. Pantoprazole (Paridem) + Clopidogrel (in Ecosprin Gold) - MODERATE DDI

Assessment: Pantoprazole is the CORRECT choice here. Still monitor for reduced antiplatelet effect; consider switching to an H2-blocker (e.g., famotidine) if GI indication is not strong.

B. Clexane (Enoxaparin) + Ecosprin Gold (Aspirin + Clopidogrel) - MAJOR BLEEDING RISK

Action: Clarify indication for Clexane. If it is for DVT prophylaxis only, consider whether the dose (60mg = therapeutic dose, not prophylactic) is appropriate. Prophylactic enoxaparin is 40mg OD. A 60mg OD dose suggests therapeutic intent, which requires justification (e.g., confirmed cardioembolism, AF, DVT/PE). If stroke is noncardioembolic, enoxaparin may need to be de-escalated or discontinued.

C. Bisoprolol (Concor Cor) + Insulin (Actrapid/NovoRapid) - MODERATE DDI

Action: Nursing staff must be briefed to check blood glucose regularly. Sweating as a hypoglycemic sign should be specifically monitored since tachycardia will not occur.

D. Ondansetron (Emset) + QT Interval Risk - MINOR ALERT

Action: Obtain baseline and follow-up ECG. Limit Emset to the minimum required duration.

ISSUE 3 - DRUG ERRORS / INAPPROPRIATE USE

A. Librium (Chlordiazepoxide 10mg BD) - INAPPROPRIATE IN THIS PATIENT

• The Beers Criteria explicitly lists benzodiazepines as potentially inappropriate in elderly patients due to increased risk of cognitive impairment, delirium, falls, fractures, and motor vehicle accidents
• In brainstem stroke, Librium will mask neurological signs - sedation, ataxia, and confusion from the drug cannot be distinguished from neurological deterioration
• Chlordiazepoxide's mechanism includes blocking brainstem reticular formation arousal - directly suppressing the very structure injured by this stroke
• No clear indication documented: why is an anxiolytic/alcohol withdrawal drug being prescribed for an acute stroke patient?

Action: REVIEW URGENTLY. What is the indication? If alcohol withdrawal is suspected, a shorter-acting benzodiazepine with safer monitoring would be more appropriate. If anxiety, non-benzodiazepine options should be considered. If no clear indication, discontinue.

B. Mucomix (N-Acetylcysteine) - UNCLEAR INDICATION

Action: Document the indication. If for thick secretions secondary to bulbar palsy or aspiration risk - appropriate. If prescribed without indication, review.

C. Insulin Concentration Error Risk - HIGH PRIORITY

Action: If both are kept, clearly label syringes, use appropriate insulin syringes (40U syringes for Actrapid), and ideally standardize to one insulin product.

ISSUE 4 - DOSE REVIEW

Summary Table

Disclaimer: This review is for clinical decision support only. All changes must be made by the treating physician after full clinical assessment of the individual patient.

Clinical Pharmacy Review - Updated Full Assessment

DRUG IDENTIFICATION - CONFIRMED COMPOSITIONS

Important correction from previous review: Ecosprin Gold 20 contains Atorvastatin, NOT rosuvastatin. This changes the drug interaction profile significantly.

ISSUE 1 - DRUG DUPLICATION

A. Thiamine Duplication - CONFIRMED, HIGH PRIORITY

Action: Stop Inj. Thiamine OD if Optineuron is continued. OR, if specific high-dose B1 is required (e.g. Wernicke's encephalopathy screen in an alcoholic patient), prescribe high-dose standalone thiamine and discontinue Optineuron.

B. Dual Insulin Prescription - POTENTIALLY DANGEROUS DUPLICATION

• Both are short-acting/rapid-acting insulins targeting the same indication
• Having both active SOS orders creates a risk that nursing staff administer BOTH sequentially
• The concentration difference (40 IU/ml vs 100 IU/ml) is a patient safety hazard (see Issue 3B below)

Action: Retain ONE insulin. Standardize to a single product with a written sliding scale. Remove the other SOS order entirely from the chart.

ISSUE 2 - DRUG-DRUG INTERACTIONS (DDI)

A. Pantoprazole (Paridem) + Atorvastatin (in Ecosprin Gold) - MODERATE DDI - NEW FINDING

Action: Monitor for muscle pain, weakness, and fatigue. Check CK levels at baseline and at follow-up. Keep atorvastatin at the lowest effective dose (20mg is reasonable). If a PPI switch is considered, rabeprazole has the least CYP3A4 interaction.

B. Pantoprazole + Clopidogrel (in Ecosprin Gold) - MODERATE DDI, WELL-MANAGED

Assessment: Appropriate PPI selection. No change needed, but avoid switching to omeprazole or esomeprazole.

C. Atorvastatin + Clopidogrel - MINOR DDI, CONTROVERSIAL

Assessment: Combination is clinically acceptable and guideline-supported for post-PTCA secondary prevention. Monitor platelet function if clinical concern arises.

D. Clexane (Enoxaparin) + Aspirin + Clopidogrel - MAJOR BLEEDING RISK - TRIPLE ANTITHROMBOTIC THERAPY

1. Aspirin 75mg (via Ecosprin Gold)
2. Clopidogrel 75mg (via Ecosprin Gold)
3. Enoxaparin 60mg SC (Clexane)

• DVT prophylaxis in a hospitalized immobile stroke patient (standard practice)
• Bridging/continuing anticoagulation if there is concern for stent thrombosis in the acute setting
• If the patient has coexisting AF (not mentioned but worth confirming)

Action:

1. Confirm and document the indication for Clexane in the chart
2. Check serum creatinine / eGFR and adjust dose if renally impaired
3. If indication is DVT prophylaxis only, consider reducing to 40mg OD
4. Assess intracranial hemorrhage risk before continuing triple therapy - obtain follow-up brain imaging

E. Bisoprolol (Concor Cor) + Insulins (Actrapid/NovoRapid) - MODERATE DDI

• Tachycardia as a warning sign of hypoglycemia will be masked
• Only sweating will remain as a clinical indicator
• This is especially dangerous in a stroke patient with altered consciousness, dysphagia, or communication difficulty (heaviness of tongue)

Action: Increase blood glucose monitoring frequency (pre-meal and 2-hour post-meal minimum). Brief nursing staff specifically about hypoglycemia masking. Document glucose targets (AHA recommends 140-180 mg/dL in acute ischemic stroke).

F. Ondansetron (Emset) - QT Prolongation Risk - MINOR

Action: Check baseline 12-lead ECG. Limit Emset to shortest effective duration. Once the patient can swallow, switch to oral domperidone or metoclopramide.

ISSUE 3 - DRUG ERRORS / SAFETY CONCERNS

A. Tab. Librium 10mg BD - INAPPROPRIATE AND POTENTIALLY HARMFUL

1. Beers Criteria 2023: All benzodiazepines are listed as potentially inappropriate in patients ≥65 years due to risk of cognitive impairment, delirium, falls, fractures, and paradoxical agitation
2. Neurological masking: In a brainstem/pontine stroke, sedation, ataxia, and confusion from chlordiazepoxide will be indistinguishable from stroke progression. This prevents accurate neurological assessment
3. Mechanism conflict: Librium's pharmacological action includes blocking brainstem reticular formation arousal - it directly suppresses the anatomical structure injured by this stroke
4. Bulbar palsy risk: The patient already has heaviness of tongue and mouth deviation. Benzodiazepine-induced hypotonia can worsen oropharyngeal muscle tone, increasing aspiration risk in a patient already vulnerable to aspiration pneumonia
5. No indication documented: There is no indication recorded for prescribing an anxiolytic/alcohol-withdrawal drug in this acute stroke admission

• Alcohol withdrawal: Use CIWA-Ar scoring; a shorter-acting agent like lorazepam is preferred in elderly with hepatic concerns
• Anxiety: Consider low-dose buspirone, SSRI, or non-pharmacological management
• Muscle spasm: Baclofen is preferred in neurological patients

Action: URGENT REVIEW. Document clinical indication. If no valid indication exists, discontinue immediately. If alcohol withdrawal is suspected, clarify with family history, use a validated withdrawal scale, and consider a safer alternative.

B. Insulin Concentration Mismatch - CRITICAL PATIENT SAFETY ERROR RISK

• Actrapid: 40 IU/ml (requires U-40 syringe)
• NovoRapid FlexPen: 100 U/ml (uses U-100 pen delivery)

Action:

1. Standardize to ONE insulin type across the prescription
2. If Actrapid is retained, ensure ONLY U-40 syringes are available at bedside
3. Post a concentration alert label on the vial
4. Conduct nursing staff verification before each insulin dose (two-nurse check)

C. Clexane 60mg OD - Dose Verification Required

Action: Verify indication, check renal function, and confirm correct dose.

ISSUE 4 - CONTEXTUAL APPROPRIATENESS REVIEW

PRIORITIZED ACTION SUMMARY

Disclaimer: This review is a clinical pharmacy decision-support document. All therapeutic changes must be reviewed and authorised by the treating physician after individual patient assessment.